Persistent Asset Partners LTD Vaxcyte, Inc. Transaction History
Persistent Asset Partners LTD
- $135 Billion
- Q2 2025
A detailed history of Persistent Asset Partners LTD transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Persistent Asset Partners LTD holds 45,499 shares of PCVX stock, worth $1.88 Million. This represents 1.1% of its overall portfolio holdings.
Number of Shares
45,499
Previous 21,139
115.24%
Holding current value
$1.88 Million
Previous $798 Million
85.31%
% of portfolio
1.1%
Previous 0.67%
Shares
3 transactions
Others Institutions Holding PCVX
# of Institutions
323Shares Held
139MCall Options Held
229KPut Options Held
160K-
Janus Henderson Group PLC London, X014.7MShares$607 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$496 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$495 Million8.5% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$411 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6MShares$248 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.45B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...